In silico resources help combat cancer drug resistance mediated by target mutations

IF 6.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY Drug Discovery Today Pub Date : 2023-09-01 DOI:10.1016/j.drudis.2023.103686
Yuan-Qin Huang , Shuang Wang , Dao-Hong Gong , Vinit Kumar , Ya-Wen Dong , Ge-Fei Hao
{"title":"In silico resources help combat cancer drug resistance mediated by target mutations","authors":"Yuan-Qin Huang ,&nbsp;Shuang Wang ,&nbsp;Dao-Hong Gong ,&nbsp;Vinit Kumar ,&nbsp;Ya-Wen Dong ,&nbsp;Ge-Fei Hao","doi":"10.1016/j.drudis.2023.103686","DOIUrl":null,"url":null,"abstract":"<div><p>Drug resistance causes catastrophic cancer treatment failures. Mutations in target proteins with altered drug binding indicate a main mechanism of cancer drug resistance (CDR). Global research has generated considerable CDR-related data and well-established knowledge bases and predictive tools. Unfortunately, these resources are fragmented and underutilized. Here, we examine computational resources for exploring CDR caused by target mutations, analyzing these tools based on their functional characteristics, data capacity, data sources, methodologies and performance. We also discuss their disadvantages and provide examples of how potential inhibitors of CDR have been discovered using these resources. This toolkit is designed to help specialists explore resistance occurrence effectively and to explain resistance prediction to non-specialists easily.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"28 9","pages":"Article 103686"},"PeriodicalIF":6.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644623002027","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Drug resistance causes catastrophic cancer treatment failures. Mutations in target proteins with altered drug binding indicate a main mechanism of cancer drug resistance (CDR). Global research has generated considerable CDR-related data and well-established knowledge bases and predictive tools. Unfortunately, these resources are fragmented and underutilized. Here, we examine computational resources for exploring CDR caused by target mutations, analyzing these tools based on their functional characteristics, data capacity, data sources, methodologies and performance. We also discuss their disadvantages and provide examples of how potential inhibitors of CDR have been discovered using these resources. This toolkit is designed to help specialists explore resistance occurrence effectively and to explain resistance prediction to non-specialists easily.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在硅资源帮助对抗癌症耐药介导的目标突变
耐药性导致灾难性的癌症治疗失败。改变药物结合的靶蛋白突变是癌症耐药(CDR)的主要机制。全球研究已经产生了大量与cdr有关的数据和完善的知识基础和预测工具。不幸的是,这些资源是分散的,没有得到充分利用。在这里,我们研究了用于探索由目标突变引起的CDR的计算资源,并根据它们的功能特征、数据容量、数据源、方法和性能分析了这些工具。我们还讨论了它们的缺点,并提供了如何利用这些资源发现潜在的CDR抑制剂的例子。该工具包旨在帮助专家有效地探索耐药性的发生,并轻松地向非专业人士解释耐药性预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Discovery Today
Drug Discovery Today 医学-药学
CiteScore
14.80
自引率
2.70%
发文量
293
审稿时长
6 months
期刊介绍: Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.
期刊最新文献
Efficacy and challenges involving combination therapies in CLL. Strategic partnerships for AI-driven drug discovery: The role of relational dynamics. Antibody-drug conjugates: prospects for the next generation. Improving access to domestic innovative medicines: characteristics and trends of approved drugs in China 2010-2024. Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1